Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTITUSSIVE vs CODEPREX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.
FDA-approved: Symptomatic relief of nonproductive cough,Off-label: Cough associated with upper respiratory tract infections, chronic bronchitis, COPD
Cough suppression (FDA-approved)
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
4-6 hours (prolonged to 10-12 hours in hepatic impairment)
Metabolism varies by agent: Dextromethorphan is metabolized via CYP2D6; codeine (opioid antitussive) is metabolized via CYP2D6 to morphine; benzonatate is metabolized by plasma esterases.
Codeine undergoes O-demethylation via CYP2D6 to morphine; also N-demethylation to norcodeine via CYP3A4; homatropine is minimally metabolized.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
Renal: 60% as unchanged drug; Hepatic metabolism: 30% (inactive metabolites); Fecal: 10%
Approximately 35-45% bound to plasma albumin.
92% (primarily to albumin)
Vd approximately 3-5 L/kg, indicating extensive tissue distribution.
1.5-2.0 L/kg (extensive tissue distribution)
Oral: approximately 40-50% due to first-pass metabolism.
Oral: 70-80% (first-pass metabolism reduces from 100% IV)
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, avoid if possible.
Hydrocodone: GFR 30-80 m L/min: no adjustment; GFR 10-29 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; GFR <10 m L/min: use with caution, consider alternative. Acetaminophen: GFR <10 m L/min: extend dosing interval to every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated due to acetaminophen toxicity risk and impaired hydrocodone metabolism.
Dextromethorphan: 2-6 years: 2.5-5 mg every 4-6 hours; 6-12 years: 5-10 mg every 4-6 hours; >12 years: adult dose. Codeine: not recommended for children due to safety concerns.
Not recommended for pediatric use (no safety and efficacy data established).
Initiate at lowest effective dose; monitor for sedation, constipation, and falls; avoid codeine if possible; dextromethorphan: 10 mg every 6-8 hours.
Start at low end of dosing range (1 tablet every 6 hours) due to increased sensitivity, reduced renal function, and risk of cognitive impairment.
N/A (No black box warning for general antitussives; specific agents like benzonatate have warnings for severe allergic reactions and accidental ingestion in children.)
Risk of respiratory depression, especially in children; contraindicated for postoperative pain management in children after tonsillectomy/adenoidectomy; contraindicated in children <12 years, and in children <18 years with risk factors for respiratory depression.
Do not exceed recommended dosage (risk of toxicity, especially with dextromethorphan abuse).,Caution in patients with respiratory depression, asthma, or chronic cough due to smoking or COPD.,Avoid in children <2 years (risk of serious adverse events).
Respiratory depression; ultra-rapid metabolizers of CYP2D6 at risk of morphine toxicity; use in breastfeeding may cause infant opioid toxicity; anticholinergic effects of homatropine; risk of abuse and dependence; CNS depression with other depressants.
Hypersensitivity to the specific antitussive agent.,Concomitant use of MAOIs or within 14 days (risk of serotonin syndrome with dextromethorphan).,Respiratory depression (especially opioid-containing antitussives).
Hypersensitivity to codeine or homatropine; respiratory depression; acute or severe bronchial asthma; GI obstruction; paralytic ileus; children <12 years; children <18 years with tonsillectomy/adenoidectomy; use with MAOIs or within 14 days; breastfeeding women with CYP2D6 ultrarapid metabolism.
Grapefruit juice may increase absorption of dextromethorphan, potentially increasing side effects. Avoid alcohol as it enhances CNS depression. No specific food restrictions for codeine, but avoid high-tyramine foods if taking MAOIs concurrently.
Grapefruit juice may inhibit CYP2D6 and reduce codeine conversion to morphine, potentially decreasing efficacy. High-fat meals may delay absorption of codeine. Avoid alcohol.
Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal respiratory depression and withdrawal if used near term; possible association with congenital malformations in first trimester, but evidence inconclusive. Avoid use in first trimester and near term.
Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retrospective studies, though risk is low. Second and third trimesters: Risk of neonatal respiratory depression if used near term; chronic use may lead to neonatal withdrawal syndrome. Avoid if possible.
Dextromethorphan: Low levels in breast milk; M/P not established; generally compatible. Codeine: M/P ratio ~2.5; risk of CNS depression in infant; use caution or avoid. Monitor infant for sedation.
Codeine is excreted into breast milk. M/P ratio is approximately 2.5. Use with caution due to risk of infant CNS depression, especially in mothers who are CYP2D6 ultra-rapid metabolizers. AAP recommends lowest effective dose for shortest duration; monitor infant for drowsiness, difficulty breathing, or poor feeding.
No specific pharmacokinetic changes require dose adjustment for dextromethorphan. Codeine metabolism may be altered due to pregnancy-induced changes in CYP2D6; individual dose titration recommended, but avoid use if possible.
No standard dose adjustment required, but avoid use in third trimester due to risk of neonatal respiratory depression. If used, use lowest effective dose for shortest duration. Monitor for signs of maternal respiratory depression; consider reduced dose in patients with decreased respiratory reserve.
Antitussives like dextromethorphan are effective for nonproductive cough but should not be used in patients with chronic productive cough due to potential suppression of necessary mucus clearance. Abuse potential exists with dextromethorphan at high doses; monitor for serotonin syndrome when combined with MAOIs or SSRIs. Codeine-containing antitussives require caution in CYP2D6 ultra-rapid metabolizers due to risk of morphine toxicity.
CODEPREX (codeine/guaifenesin) is a combination antitussive/expectorant. Codeine is a prodrug metabolized by CYP2D6 to morphine; ultra-rapid metabolizers risk toxicity. Avoid in children <18 years due to respiratory depression risk. Use with caution in patients with COPD or respiratory insufficiency. Constipation is common; consider prophylactic laxatives.
Take only for dry, hacking cough; do not use for cough with phlegm unless directed by a doctor.,Do not exceed recommended dose; excessive use can lead to serious side effects including confusion, hallucinations, and rapid heart rate.,Avoid alcohol and sedatives as they may increase drowsiness and respiratory depression.,Seek medical attention if cough persists >1 week, or is accompanied by fever, rash, or headache.,Do not combine with other cough/cold products containing the same active ingredients.
Do not exceed recommended dose; may cause drowsiness, avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants as they increase sedation and respiratory depression risk.,Do not use in children under 18 years of age due to risk of serious breathing problems.,Contact your doctor if cough persists for more than 7 days or is accompanied by fever, rash, or persistent headache.,May cause constipation; increase fluid and fiber intake, and consider a stool softener if needed.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTITUSSIVE vs CODEPREX, answered by our medical review team.
ANTITUSSIVE is a Antitussive that works by Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).. CODEPREX is a Antitussive Combination that works by Codeine is a prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, while homatropine is an anticholinergic that reduces respiratory secretions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTITUSSIVE and CODEPREX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTITUSSIVE is: For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.. The standard adult dose of CODEPREX is: Adults: 1 tablet (containing 5 mg hydrocodone and 325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTITUSSIVE and CODEPREX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTITUSSIVE is classified as Category C. Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal . CODEPREX is classified as Category C. Based on available data, codeine is pregnancy category C. First trimester: Avoid due to possible association with congenital malformations (e.g., cardiovascular defects) from retro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.